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      ABSTRACT 
 
Objective: The purpose of this careful EBM review is to determine whether lisdexamfetamine 
dimesylate (LDX) is safe and effective in reducing attention-deficit/hyperactivity disorder 
(ADHD) symptoms. 
 
Study Design: A systematic review of two randomized controlled studies and one double-blind, 
2-arm, parallel-group placebo-controlled RWP published between 2011-2014, all in the English 
language.  
 
Data Sources: Two randomized controlled trials and one double-blind, 2-arm, parallel-group 
placebo-controlled RWP published between 2011 and 2014 which were found using PubMed 
and Cochrane databases. 
 
Outcomes Measured: ADHD global symptomatic improvement was measured using Clinical 
Global Impressions – Severity of Illness (CGI-S), Clinical Global Impression-Improvement 
(CGI-I) and ADHD Rating Scale-IV (ADHD-RS-IV). Safety was measured using treatment-
emergent adverse events (TEAEs). 
 
Results: Two randomized controlled trials and one double-blind, 2-arm, parallel-group placebo-
controlled RWP revealed that using LDX helped reduce ADHD symptoms greater than the 
placebo it was compared against. The most common side effects caused by LDX were a 
headache, insomnia, and decreased appetite. 
 
Conclusion: The literature utilized in this EBM project revealed that children and adolescents 
that used Vyvanse, demonstrated improvement in attention-deficit/hyperactivity disorder 
(ADHD) symptomatology. Additionally, it was found that LDX was safe for use as the side 
effects were benign.  
 
Key Words: ADHD, Stimulant Therapy, Lisdexamfetamine Dimesylate
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INTRODUCTION 
  ADHD is a disorder of the brain characterized by a continuous pattern of hyperactivity 
and impulsivity, or inattention which can impede development and functioning.1 This paper 
evaluates two randomized control trials (RCTs) and one double-blind, two-arm, parallel-group, 
placebo controlled study to determine ADHD global symptomatic improvement/safety versus a 
placebo.  
 According to the Centers for Disease Control and Prevention (CDC) in 2011, 11% of 
United States children (approximately 6,400,000 children aged 4-17 years old) were diagnosed 
with ADHD.2 It is estimated that $42.5 billion are spent each year in the U.S.A. to treat this 
condition.3 The cost of lisdexamfetamine dimesylate (brand name: Vyvanse) for one diagnosed 
with ADHD is approximately $885 for a 100 day supply, and no generic is available.4 Recently, 
the CDC estimated that there are 9 million health care visits each year in the United States which 
result in a primary diagnosis of ADHD.5 
 It is known that men develop ADHD more often compared to their female counterparts.1 
Scientific experts cannot pinpoint what causes ADHD. It is postulated that certain factors such as 
traumatic brain insults, exposure to environmental toxins and alcohol/drug usage during 
gestation contribute to the development of this disorder.1 Although much is unknown about this 
disorder, there are many safe and effective treatment modalities. 
 Psychotherapy such as cognitive behavioral therapy (CBT) and family therapy are used to 
treat this condition in combination with medication.1 Stimulant medications (like 
methylphenidate, dextroamphetamine saccharate, and lisdexamfetamine dimesylate) are the gold 
standard medications for treating symptoms of ADHD.1 Finally, non-stimulant medications (i.e. 
atomoxetine) are only utilized if the stimulant medications are contraindicated.1  
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 All the treatment options that were presented in the previous paragraph have been shown 
to be safe and improve symptomatology in patients with ADHD. Lisdexamfetamine dimesylate 
may be used as a safe and effective alternative to older stimulant medications such as 
methylphenidate and dextroamphetamine saccharate.  
OBJECTIVE 
 The purpose of this careful EBM review is to determine if lisdexamfetamine dimesylate 
is safe and effective in reducing ADHD symptoms. 
METHODS 
 This review focused on children and adolescents (male and female) ages 6-17 with 
attention-deficit/hyperactivity disorder. In all three studies, the intervention studied was 
lisdexamfetamine dimesylate. The comparison group in Findling et al. and Coghill DR et al. was 
a placebo.6,7 In Coghill D, Banaschewski T, Lecendreux M, et al. the comparison group was 
osmotic-release oral system methylphenidate (OROS-MPH) and placebo.8 Although multiple 
outcomes were addressed in all three studies, this review focused on ADHD symptomatic 
improvement and safety. Two randomized controlled trials and one double-blind, 2-arm, parallel-
group placebo-controlled RWP were included. 
 The keywords that were utilized to ascertain these articles were ADHD, stimulant 
therapy, and lisdexamfetamine dimesylate. All of the articles were published in English, were 
peer-reviewed, published and chosen from PubMed and Cochrane. Articles were selected based 
on the whether they were POEMs (patient oriented evidence that matters). Additionally, they 
were selected based on their relevance in regards to the chosen research question.  
 The inclusion criteria utilized for this review was based on whether the articles were 
relevant to the clinical question.  Additional inclusion factors were experimental studies, RCTs, 
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POEMs, and published between 2011-present. Exclusion criteria were patients under the age of 6 
or over the age of 17 and studies that did not have LDX and their intervention. Statistics that 
were utilized included p-values, relative risk reduction (RRR), Relative benefit increase (RBI), 
absolute risk reduction (ARR), and numbers needed to treat (NNT). Table 1 includes 
demographics and additional inclusion and exclusion criteria that were used in this review. 
Table 1 – Demographics of included studies  
Study Type Number 
of 
patients 
Age (years 
old) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D  Interventions 
Coghill, 
D (8) 
RCT 336 6-17 Kids 6-12 
years old and 
adolescents 
13-17 years 
old of both 
genders. With 
ADHD   
(moderate 
severity) age 
appropriate 
intelligence, 
able to 
swallow pills 
and blood 
pressure 
measurements 
within the 
95th percentile 
for sex, 
height, and 
age. 
The presence 
of comorbid 
psychiatric 
diagnoses 
(with 
significant 
symptoms). 
BMI is 
greater than 
the 97th 
percentile. 
Patients with 
specific 
diseases or 
conditions 
(i.e. 
Tourette’s 
syndrome, 
smokers, and 
substance 
abusers). 
Finally, 
patients who 
were 
currently 
taking 
ADHD meds 
that 
adequately 
controlled 
their 
symptoms. 
140 
patients 
dropped out 
of the study 
Lisdexamfetamine 
dimesylate 
(30,50,70 mg/d) 
vs. placebo vs. 
OROS-MPH. For 
4 weeks study 
participants were 
randomly placed 
into one of three 
treatment 
categories. This 
was followed by a 
3 week dose 
maintenance 
period. 
Coghill, 
DR (7) 
Double-
blind, 2-
arm, 
parallel-
group, 
placebo-
276 6-17 Same criteria 
as above 
except patient 
had to 
complete 4 
weeks of 
Inability to 
respond to 
OROS-
MPH. US 
patients who 
failed to 
119 
patients 
dropped out 
of the study 
Lisdexamfetamine 
dimesylate 
(30,50,70 mg/d) 
vs. placebo for a 6 
week randomized 
withdrawal 
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controlled 
RWP 
double-blind 
treatment and 
1-week post-
washout 
treatment 
without 
experiencing 
any clinically 
significant 
events. 
ADHD-RS-
IV total score 
of 28 and 
above.  
respond to 
more to more 
than 1 
adequate 
course of 
amphetamine 
therapy. 
Patients with 
comorbid 
psychiatric 
diagnoses 
with 
significant 
symptoms. 
period. Efficacy 
was measured 
using the 
proportion of 
patients meeting 
treatment failure 
criteria. 
Finding, 
RL (6) 
RCT 314 13-17 Ages 13 to 17 
years old. 
They were 
required to 
meet the 
DSM-IV-TR 
diagnostic 
criteria for 
ADHD. 
Same as 
above. 
49 patients 
withdrew 
from the 
study 
Lisdexamfetamine 
dimesylate 
(30,50,70 mg/d) 
vs. placebo. 
 
OUTCOMES MEASURED 
  Reduction of ADHD symptoms using lisdexamfetamine dimesylate vs. placebo was 
measured using Clinical Global Impressions - Severity of Illness (CGI-S), Clinical Global 
Impression Improvement (CGI-I) and ADHD Rating Scale IV (ADHD-RS-IV).  Safety was 
measured using treatment emergent adverse events (TEAEs) which were defined as drug 
reactions that began or got worse following the 1st administration of lisdexamfetamine 
dimesylate and 3 days after the patient stopped taking the medication.8  
RESULTS 
Findling et al. assessed whether or not lisdexamfetamine dimesylate was effective in 
treating ADHD symptomatology in 314 adolescents aged 13-17 years old.6 Of the original 314 
adolescents 49 patients left before completing the study (276 patients finished the study).6 
Outcomes were measured using CGI-I results were taken at baseline and each week after that for 
4 weeks. It was shown that at endpoint 69.1% (EER) of patients who were taking LDX showed 
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symptomatic improvement regarding hyperactivity/impulsivity compared to the placebo which 
only showed a 39.5% (CER) improvement (p-value < 0.0001).6 Relative benefit increase (RBI) 
of 0.75, absolute benefit increase (ABI) of 29.65% and numbers needed to treat (NNT) 4. Refer 
to Table 2 for mathematical calculations. 
Table 2 
CER EER EER- CER 
CER 
EER - CER 1/ABI 
39.5% 69.1% 0.691-0.395/0.395 = 
0.75 
69.1%-39.5% = 
29.65 
1/29.6% = 4 patients 
 
In the study by Coghill D et al. the authors assessed whether LDX was safe and efficient 
in treating young adults and children diagnosed with ADHD.8 In this study, safety was reported 
as treatment emergent adverse (TEAEs). Only 3 out of 111 patients that took LDX experienced 
serious TEAEs even though the authors indicated it was not attributed to the medication usage.8 
In the control group that was taking OROS-MPH, 1 patient had a serious TEAE (overdose) 
which required his removal from the study.8 Of the original 336 participants, 196 completed the 
study. Efficacy outcomes were measured via ADHD Rating Scale IV (ADHD-RS-IV) at the 
beginning of the study and following the completion of the participants. The confidence interval 
and p-value for the efficacy of ADHD symptomatic improvement for those taking LDX were 
95% and less than 0.001 respectively.8 It was shown that 78% (EER) of patients who were taking 
Vyvanse showed symptomatic improvement regarding hyperactivity and impulsivity.8 The 
placebo on the other hand only showed a 14% (CER) improvement.8 Relative benefit increase 
(RBI) of 4.75, absolute benefit increase (ABI) of 64% and a small numbers needed to treat 
(NNT) of 2. All calculations can be seen in Table 3.  
Table 3 
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CER EER EER- CER 
CER 
EER - CER 1/ABI 
14% 78% 0.78-0.14/0.14 = 4.57 78%-14% = 64% 1/64% = 2 patients 
 
 In the randomized withdrawal study by Coghill DR et al. the author wanted to determine 
whether the discontinuation of LDX would cause a return of ADHD symptomatology based on a 
≥ 50% increase in ADHD Rating Scale IV (ADHD-RS-IV) from baseline.7 Of the 276 patients 
that began the study 119 dropped out.7 As seen in Table 4, patients randomly assigned to the 
LDX group had a lower treatment failure rate 15.8% versus those assigned to the placebo arm of 
which 67.5% met treatment failure criteria.7 This meant more people dropped out of the placebo 
group than LDX group at the end of the study. Relative risk reduction (RRR), absolute risk 
reduction (ARR) and numbers needed to treat (NNT) as seen in Table 4 were 3.27, 51.7%, and 2 
patients respectively. A 95% confidence interval and a p-value of < 0.001 were reported by the 
authors of this study.7 
Table 4 
  
DISCUSSION 
One limitation of all three studies was that they looked at children and adolescents only 
(ages 6-17 years old). Another limitation was that two of the articles had authors that were 
employed by the pharmaceutical company which is the developer of LDX.7,8  
New literature published by a neutral party indicates that adults diagnosed with ADHD 
ages 18-55 experienced symptomatic relief and are more focused throughout the workday when 
CER EER EER – CER 
CER 
EER - CER 1/ARR 
15.8% 67.5% 0.675-0.158/0.158 = 
3.27 
67.5%-15.8% = 
51.7% 
1/51.7% = 2 patients 
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treated with LDX.9 Henceforth, LDX achieved similar results in children and adults alike. 
Although LDX is effective, one issue with this medication is the cost.  
Without insurance, LDX costs upwards of $885 for a 100 day supply.4 Even those with 
insurance such as BlueCross Northeastern Pennsylvania may pay upwards of $100 for a 90 day 
supply adding up to over $400 each year.10 Additionally, it is important to note that some of the 
reported side effects of LDX are not trivial. Side effects included but were not limited to 
seizures, tremors, and mood swings have been reported.11 
CONCLUSION 
 Based on the systematic review of the three research articles LDX is safe and efficient in 
treating ADHD symptomatology when compared against OROS-MPH.8 Additionally, it is 
important to note that LDX is theorized to have a diminished abuse potential when compared to 
older medications like amphetamine sulfate.12 One flaw of note, was approximately 140 people 
did not complete the Coghill D et al. study, so it was a small sample size.  
 Future research is warranted to see if LDX is more effective than other stimulant 
medications such as dextroamphetamine saccharate.  Finally, subsequent research should focus 
on whether combined behavioral and LDX therapy is more effective at treating ADHD 
symptomatology compared to LDX monotherapy.
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